anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides application of a novel anthracycline compound SZ-685C with a structure shown as a formula I in preparing anti-breast cancer medicines. The invention proves that the novel anthracycline compound SZ-685C has very strong anti-breast cancer activity through in vitro experiments and in vivo experiments. The in vivo experiments prove that the IC50 (inhibition concentrations 50) of the compound SZ-685C on breast cancer cells MCF-7 and MDA-MB-435 and human immortalized mammary epithelial cells MCF-10A after the compound SZ-685C acts for 48 hours are 3.01mu m, 7.52mu m and 49.63mu m respectively, which demonstrates that the compound SZ-685C shows the good characteristic of serving as an anti-breast cancer medicine, and the compound SZ-685C has small toxic and side effects on normal cells. Meanwhile, the in vivo experiments prove that the compound SZ-685C can obviously inhibit the growth of breast cancer transplanted tumors in a naked mouse, and the maximum tumor inhibition rate reaches more than 60 percent. Further, the anti-tumor mechanics research proves that the compound SZ-685C can induce tumor cells to die by both an endogenous way and an exogenous way which are depended by Caspase to realize the stronger anti-cancer efficiency, thereby laying the foundation for developing the novel anti-breast cancer candidate medicines with high efficiency and low toxicity. The structure of the compound is shown as the formula I.
Participants will receive treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 1; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 2; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
The present disclosure provides antibodies that bind complement CIs protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions. The present disclosure provides an isolated. humanized monoclonal antibody that inhibits cleavage of complement component G4, where the antibody does not inhibit cleavage of complement component C2. In some cases, the antibody inhibits a component of the classical complement pathway; in some cases, the classical complement pathway component is CIs. In some instances, the antibody does not inhibit protease activity of CIs.
The efficacy and safety of CIALIS for once daily use for the treatment of the signs and symptoms of BPH was evaluated in 3 randomized, multinational, double-blinded, placebo-controlled, parallel-design, efficacy and safety studies of 12 weeks duration. Two of these studies were in men with BPH and one study was specific to men with both ED and BPH [see Clinical Studies (14.4)]. The first study (Study J) randomized 1058 patients to receive either CIALIS 2.5 mg, 5 mg, 10 mg or 20 mg for once daily use or placebo. The second study (Study K) randomized 325 patients to receive either CIALIS 5 mg for once daily use or placebo. The full study population was 87% White, 2% Black, 11% other races; 15% was of Hispanic ethnicity. Patients with multiple co-morbid conditions such as diabetes mellitus, hypertension, and other cardiovascular disease were included. 

The primary efficacy endpoint in the two studies that evaluated the effect of CIALIS for the signs and symptoms of BPH was the International Prostate Symptom Score (IPSS), a four week recall questionnaire that was administered at the beginning and end of a placebo run-in period and subsequently at follow-up visits after randomization. The IPSS assesses the severity of irritative (frequency, urgency, nocturia) and obstructive symptoms (incomplete emptying, stopping and starting, weak stream, and pushing or straining), with scores ranging from 0 to 35; higher numeric scores representing greater severity. Maximum urinary flow rate (Qmax), an objective measure of urine flow, was assessed as a secondary efficacy endpoint in Study J and as a safety endpoint in Study K. 

The results for BPH patients with moderate to severe symptoms and a mean age of 63.2 years (range 44 to 87) who received either CIALIS 5 mg for once daily use or placebo (N=748) in Studies J and K are shown in Table 19 and Figures 5 and 6, respectively. 

In each of these 2 trials, CIALIS 5 mg for once daily use resulted in statistically significant improvement in the total IPSS compared to placebo. Mean total IPSS showed a decrease starting at the first scheduled observation (4 weeks) in Study K and remained decreased through 12 weeks. 

Figure 5: Mean IPSS Changes in BPH Patients by Visit in Study J 

Figure 6: Mean IPSS Changes in BPH Patients by Visit in Study K 

In Study J, the effect of CIALIS 5 mg once daily on maximum urinary flow rate (Qmax) was evaluated as a secondary efficacy endpoint. Mean Qmax increased from baseline in both the treatment and placebo groups (CIALIS 5 mg: 1.6 mL/sec, placebo: 1.2 mL/sec); however, these changes were not significantly different between groups. 

In Study K, the effect of CIALIS 5 mg once daily on Qmax was evaluated as a safety endpoint. Mean Qmax increased from baseline in both the treatment and placebo groups (CIALIS 5 mg: 1.6 mL/sec, placebo: 1.1 mL/sec); however, these changes were not significantly different between groups.
Latanoprost is a prostaglandin F2α analogue. Its chemical name is isopropyl-(Z)-7[(1R,2R,3R,5S)3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl] cyclopentyl]-5-heptenoate. Its molecular formula is C26H40O5 and its chemical structure is:

Latanoprost is a colorless to slightly yellow oil that is very soluble in acetonitrile and freely soluble in acetone, ethanol, ethyl acetate, isopropanol, methanol, and octanol. It is practically insoluble in water.

Latanoprost Ophthalmic Solution 0.005% is supplied as a sterile, isotonic, buffered aqueous solution of latanoprost with a pH of approximately 6.7 and an osmolality of approximately 267 mOsmol/kg. Each mL of Latanoprost Ophthalmic Solution contains 50 mcg of latanoprost. Benzalkonium chloride, 0.02% is added as a preservative. The inactive ingredients are: sodium chloride, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate anhydrous, and water for injection. One drop contains approximately 1.5 mcg of latanoprost.
PURPOSE:To obtain an anti-inflammatory drug suppressing side effects related to gastrointestinal disorder, containing a melanin-based substance obtained from ink of cuttlefish or octopus. CONSTITUTION:Ink of cuttlefish or octopus is incorporated with an alkalizing agent such as caustic soda or potash soda, adjusted to pH6-12, homogenized by a homogenizer, filtered by filter cloth, dialyzed and lyophilized to give a melanin-based substance. The substance is pharmaceutically manufactured by a conventional procedure as it is or blended with a carrier and an excipient for proper preparation and pharmaceutically manufacture to give the aimed substance. The substance can be made into a dosage form such as powder, granule, tablet, capsule or injection and a dose is 50-500mg/day per adult. Properties of the melanin-based substance; black amorphous powder; solubility; slightly soluble in water and insoluble in ethanol, ethyl acetate and benzene; melting point: >=300 deg.C; elemental analysis value: C 47-50%, H 3-4%, O 38-41%, N 8-9% and ash 0.06-0.08%; molecular weight: mixture of substance having 25,000mol.wt. and substance having >=160,000.
<P>PROBLEM TO BE SOLVED: To provide improved autologous T cell vaccines and methods for their production.  <P>SOLUTION: The present invention relates to the improved autologous T cell vaccines and the methods for their production. The invention is also directed to methods for treating T cell-associated diseases such as multiple sclerosis and rheumatoid arthritis using autologous T cell vaccines. In one embodiment, a plurality of mononuclear cells including the T cell are obtained from peripheral blood mononuclear cells (PBMCs) of a patient. In another embodiment, the plurality of mononuclear cells are obtained from the cerebrospinal fluid (CSFMCs) of the patient. In one embodiment, one or more multiple sclerosis associated antigens are myelin antigens selected from the group consisting of myelin basic protein, proteolipid lysoprotein, myelin oligodendrocyte glycoprotein, and fragments thereof.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Biologically active photo- and oxy-stable plant pigment units are prepared from raw plant material by forming from such material a hydrosol of colloidal dispersoids containing pigment protein and lipin constituents, filtering, separating the plant pigment units from the hydrosol by centrifuging or by electro-dialysis, and drying the pigments under careful conditions.  The mother liquor from which the pigments have been separated may, if desired, be further treated to separate cytoplasmic plant protein.  The raw material such as fresh leaves, raw vegetables or fruits is washed to remove surface dirt, then chopped into small pieces and finally ground in a colloid mill with a small quantity of distilled water. The filtration step which follows is carried out through paper or a fritted glass filter. If the pigment units are to be separated by centrifugation the so-called super-centrifuges which revolve at 2900 r.p.m. are used. If electrodialysis is used, collodion sacs are employed as the dialysing membrane, the hydrosol being on one side of the membrane and distilled water on the other and a current of 110 volts and 1.8 to 2 amperes is passed.  The drying is preferably carried out in dry air at about 30 DEG  C.  The dried pigments so obtained may be further separated by selective-solvent partition or by chromatographic adsorption. Examples are given starting with spinach, parsley and tomato, and a description of the therapeutic uses is included.
PURPOSE:To obtain a composition containing a higher fatty acid or its ester and having excellent dispersibility in water, by adding a higher fatty acid or its ester in liquid state to cyclodextrin and mixing the product. CONSTITUTION:A water-dispersible composition containing a higher fatty acid or its ester is produced by adding a higher fatty acid (e.g. gamma-linolenic acid) or its ester in liquid state to cyclodextrin and mixing the product. A higher fatty acid or its ester is an oily substance immiscible with water. The oily substance can be uniformly dispersed in various aqueous solutions or aqueous slurries and in some oily substances by converting the substance to the present composition. Accordingly, the present composition can be utilized in various fields taking advantage of the physiological activity or pharmacological activity of the higher fatty acid or its ester. The amount of the higher fatty acid or its ester is 1-30pts.wt. per 100pts.wt. of cyclodextrin.
BACKGROUND: Diabetes and obesity are associated with altered lipid metabolism and hepatic steatosis. Studies suggest that increases in lipid accumulation in these patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are not uniform for all lipid components. This study evaluates this variation.
METHODS: A comprehensive lipidomic analysis of different lipid groups, were performed on liver tissue and plasma samples obtained at the time of histology from a well-defined cohort of 72 MASLD participants. The lipid profiles of controls were compared to those of MASLD patients with obesity, diabetes, or a combination of both.
RESULTS: MASLD patients without obesity or diabetes exhibited distinct changes in the lipid profile of their liver tissue. The presence of diabetes or obesity further modified these lipid profiles (e.g., ceramide 47:7;4O), with positive or negative correlation (p < 0.05). A step-wise increase (long-chain fatty acids, triglycerides, and ceramides) or decrease (ultra-long fatty acids, diglycerides, and phospholipids) for lipid groups was observed compared to control among patients with MASLD without obesity or diabetes to MASLD patients with obesity as a single risk factor, and MASLD patients with obesity and diabetes. Changes in lipids observed in the plasma did not align with their corresponding liver tissue findings.
CONCLUSION: The changes observed in the composition of lipids are not similar in patients with obesity and diabetes among those with MASLD. This highlights the different metabolic processes at play. The presence of obesity or diabetes in patients with MASLD exacerbates these lipid derangements, underscoring the potential for targeted intervention in MASLD patients.
No history of addiction to any substance or gambling. Less than 20 lifetime cigarettes or equivalent.
Use of avarol (I) (or a deriv.), as antioxidant and inhibitor of enzymes involved in synthesis of prostaglendins and leukotrienes, is new. USE/ADVANTAGE - (I) is described in DE3427383. Derivs. are described in US4946869. They can be used in treatment of inflammatory systemic disorders and skin disorders, esp. in treatment of rheumatic diseases, autoimmune diseases, Psoriasis vulgaris, atopic dermatitis, Crohn's disease, colitis ulcerosa and inflammation of skin, mucous membranes and the associated blood vessel systems.
FIELD: surgery. SUBSTANCE: biomaterial, in particular hyaluronic acid benzyl ester, in which 75 to 100% of hyaluronic acid carboxyl groups are substituted. Up to 25% of carboxyl groups can be substituted via esterification by C10-C20- aliphatic alcohol, provided that at least 80% of carboxyl groups are esterified. Biomaterial is made in the form of membrane, gauze, woven or nonwoven web or gel. Optional biomaterial contains at least one hyaluronic acid derivative, which is auto-cross-linked derivative wherein 0.5 to 20% of hyaluronic acid carboxyl groups are cross-linked hydroxyl groups of the same or another hyaluronic acid molecule. Postoperative commissures are prevented by applying above-described biomaterial onto tissue involved into surgical operation. EFFECT: created commissure formation barrier until healing completion to avoid such problems as infection, calcification of implants, formation of scar, etc. 12 cl, 10 dwg, 9 tbl, 18 ex
PROBLEM TO BE SOLVED: To obtain a cosmetic excellent in viscosity stability, good in spread and compatibility at the time of application onto the skin and readily washed away by using a clay mineral together with a polyhydric alcohol. SOLUTION: This cosmetic contains (A) a clay mineral (preferably kaolin) and (B) a polyhydric alcohol without substantially containing water and preferably further contains (C) a polyhydric alcohol-soluble polymer and (D) an activated zeolite. Furthermore, the amounts of the formulated ingredients in the whole composition are preferably 5-60 wt.% of the ingredient A, 1-95 wt.% of the ingredient B (e.g. polyethylene glycol), 0.01-10 wt.% of the ingredient C (e.g. hydroxypropyl cellulose) and 1-60 wt.% of the ingredient D  e.g. the one represented by the formula MxO.Al2O3.ySiO2.zH2O [M is an alkali metal or the like; (x), (y) and (z) are each an optional number]}.
1,228,431. Carpet backing. JUTE INDUSTRIES Ltd. 20 June, 1969 [21 March, 1968], No. 13687/68. Headings D1K and D1R. A carpet backing composed of a woven fabric of flat warp and weft yarns formed from a synthetic resinous material has a mat of fibres or fleece laid over it and is fed to a needling machine where the fibres or fleece are needled to the intersections of the warp and weft yarns thereby securing them. The resinous material may be polypropylene or polyethylene and the woven fabric may be heat set before or after needling. The fibres or fleece may be of viscose rayon.
PURPOSE: To obtain a safe hair dye composition effective for preventing or ameliorating contact dermatitis and suppressing inflammatory dermatic diseases and capable of keeping the hair-dyeing property by compounding an extract of comfrey leaf to a p-phenylenediamine derivative or its salt. CONSTITUTION: This hair dye composition is produced by compounding an extract of comfrey leaf as a natural vegetable component with one or more kinds of solvents selected from water, hot water, a lower alcohol and a polyol- based organic solvent to prevent or ameliorate contact dermatitis caused by a p-phenylenediamine derivative or its salt used as an intermediate for hair dye. The p-phenylenediamine derivative or its salt is e.g. p-phenylenediamine or N-phenylene-p-phenylenediamine acetate. Comfrey is a perennial plant native to Europe and belonging to the genus Symphytum, family Boraginaceae. The composition can suppress various inflammatory diseases of scalp and skin and is usable as a hair dye, hair-dyeing shampoo, hair-dyeing rinse, hair-dyeing treatment agent, etc.
Overview of Experimental Design: The study is a randomized controlled clinical trial designed to examine the disease-altering capabilities of a 12 month aerobic exercise program for individuals with PD. A total of 252 individuals with PD will be randomized into 1) a home-based aerobic exercise program, or 2) a usual and customary care (UCC). Subjects in the home exercise group will receive a commercially available Peloton indoor stationary bicycle delivered to their home for a 12 month exercise period. Individuals in the UCC group will continue their current level of physical activity. Both groups will undergo a series of motor and non-motor assessments at enrollment, 6 months, and 12 months to measure disease progression of the 12 month period. Additionally, data will be used to develop a prognostic model to predict 12-month change in Movement Disorder Society - Unified Parkinson's Disease Rating Scale III (MDS-UPDRS III) for patients participating in a home-based high-intensity aerobic exercise program.
Adolescence period; It is an important stage of development in which the self-concept develops, self-related schemas are created and carried into adulthood. During this formative period of life; Adolescents experience increasing levels of uncertainty and self-consciousness as they progress through the task of identity formation. It is greatly influenced by social interactions, especially interactions with peers.Children and adolescents with epilepsy are at increased risk for social problems, reduced social competence, poor social skills, and deficits in social communication compared to healthy children. Compared to youth with other chronic diseases, youth with epilepsy have higher rates of comorbid neurological disorders, academic failure, poor social skills, stigma, poor quality of life, and behavioral health problems (e.g., anxiety, depression). They often experience low quality of life because they feel unsafe and fear having a seizure in public. In a study aiming to investigate the factors affecting the level of social anxiety in epilepsy, it was concluded that social anxiety is independently associated with low quality of life. In a meta-analysis study; It was concluded that the motivational interviewing method applied by nurses increased the quality of life of individuals with chronic diseases. When the literature was examined, no study was found that addressed the motivational interviewing technique applied to the social anxiety and quality of life of adolescents with epilepsy. Motivational Interviewing Technique applied to adolescents with epilepsy; It is thought that it will be effective in reducing social anxiety and increasing the quality of life by enabling adolescents to become aware of their situation, get rid of the ambivalent (opposite emotional state) they experience, and take action to change.
The invention designs and synthesizes a carboxylation platinum prodrug, and prepares a coordination nanometer inner core by utilizing the coordination of ions and the prodrug. The nano inner core is coated with lipid, and photosensitizer is dispersed in the nano inner core to construct prodrug nano carrier. The phagocytic function of macrophages (BMDM) is used for loading nano prodrug to prepare a near infrared light (NIR) activated macrophage-nano prodrug delivery system. The system has the characteristics of high drug loading capacity, light-operated activation and self activity and function retention, and can realize high-efficiency and synchronous drug delivery of primary tumor and metastatic tumor after intravenous injection. Meanwhile, after primary tumor NIR irradiation is given, the medicine can be triggered to be rapidly released, chemotherapy-photodynamic combined treatment is realized, and the purposes of killing tumor cells and activating an immune system are achieved. The dual treatment of primary and metastatic tumors is finally realized through the combination of three modes of chemotherapy, photodynamic and immunity.
Carefully consider the potential benefits and risks of etodolac and other treatment options before deciding to use etodolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). 

After observing the response to the initial therapy with etodolac, the dose and frequency should be adjusted to suit an individual patient's needs. 

Dosage adjustment of etodolac is generally not required in patients with mild to moderate renal impairment. Etodolac should be used with caution in such patients, because, as with other NSAIDs, it may further decrease renal function in some patients with impaired renal function (see Error! Hyperlink reference not valid.Error! Hyperlink reference not valid.).
PURPOSE: Enhanced recovery after surgery (ERAS) protocols are widely used in the post-operative care of hernia patients. Despite their prevalence, an absence of published consensus guidelines creates significant heterogeneity in practices. The aim of this study was to evaluate elements in ERAS protocols utilized in ventral hernia repair from institutions across the United States and provide consensus recommendations for each identified element.
METHODS: Institutional members of the Abdominal Core Health Quality Collaborative (ACHQC) Quality Improvement (QI) committee submitted current ERAS protocols. Items within each protocol were classified as "elements", then assigned a topic. Any topic with ≥ 2 elements from separate institutions were labeled as a "theme," then grouped by stage in the patient care cycle. A brief review of current evidence was provided in addition to a ACHQC QI committee consensus statement.
RESULTS: A total of 295 elements from 6 tertiary referral centers specializing in hernia care were compiled into 24 themes and grouped by four separate stages: Pre-Admission Optimization, Pre-Operative Care, Intra-operative Care, and Post-Operative Management.
CONCLUSION: This article represents a multi-institutional review of ERAS protocols for ventral hernia repair and identifies common themes that may provide the framework for a unified ERAS protocol in hernia surgery. Future work may serve to develop societal guidelines defined specifically for enhanced recovery in ventral hernia repair.
Intervention: Stress-dose Steroids. Patients will receive methylprednisolone 40 mg (on the first, postenrollment cardiopulmonary resuscitation cycle. Otherwise, advanced life support will be conducted according to the 2015 guidelines for resuscitation). After resuscitation, patients will be treated with stress-dose hydrocortisone 240 mg daily for 7 days maximum, followed by gradual taper over the next 2 days.
Subjects assigned to this arm will not be offered access to the mobile app during the first 8 weeks of their participation. Subjects will be asked to begin using the app eight weeks after randomization. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week time point (just before subject begins using the mobile app) and 16 week time point.